Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  MK-677 vs Ipamorelin: Simple Research Comparison Guide

MK-677 vs Ipamorelin: Simple Research Comparison Guide

Jun 11, 2026 4 min Growth Hormone
TL;DR
MK-677 is a once-daily oral compound that mimics GH-releasing peptides, while Ipamorelin is an injectable peptide with a shorter action window. Research doses differ significantly between the two. Neither is approved for human use beyond clinical trials, and safety questions remain open for both.

Two Compounds, One Goal: More Growth Hormone

Your body releases growth hormone (GH) in pulses. GH helps build muscle, burn fat, and repair tissue. Both MK-677 and Ipamorelin are called growth hormone secretagogues — a fancy term for compounds that tell your pituitary gland to release more GH. But they work differently, and research treats them very differently too.

This post is for educational purposes only. Neither compound is approved as a medicine for healthy adults. Always read primary research before drawing conclusions.

What Is MK-677?

MK-677 (also called Ibutamoren) is a non-peptide, orally active secretagogue. That means you swallow it — no needle required. It mimics a hormone called ghrelin and latches onto GH receptors in the brain.

A landmark 1998 randomized, placebo-controlled trial gave eight healthy volunteers 25 mg of MK-677 orally per day for seven days during caloric restriction. GH levels spiked, IGF-1 (a key growth signal) rose significantly, and nitrogen loss — a marker of muscle breakdown — was reversed compared to placebo.[1] That study used 25 mg/day as its research dose.

Animal studies add nuance. In rats given 4 mg/kg daily for six weeks, GH spiked initially but the body adapted — a process called desensitization — blunting the effect over time.[5] Long-term human data are limited.

On the safety side, a 2025 case report documented liver enzyme elevation (called transaminitis) in a healthy man in his early 30s who used MK-677 for two months. Liver tests normalized after stopping.[2] A separate case report noted changes in serum lipids and liver enzymes after combined MK-677 and LGD-4033 use.[6] These are case reports — small data — but they flag real signals worth watching.

What Is Ipamorelin?

Ipamorelin is a peptide — a short chain of amino acids. Because peptides break down in the stomach, it must be injected, not swallowed. It is highly selective, meaning it triggers GH release with less impact on cortisol or prolactin than older secretagogues.

Ipamorelin is frequently studied alongside CJC-1295, another peptide that extends its GH pulse. A 2026 sports medicine review noted that the CJC-1295 + Ipamorelin combination showed improved muscle function in animal models of glucocorticoid-induced muscle loss — though the authors stressed these findings are limited to animal studies and human orthopaedic data are lacking.[4] A broader 2026 orthopaedics review also listed Ipamorelin among GH secretagogues that activate IGF-1 signaling and satellite cell repair, again noting that clinical trials are currently scarce.[3]

Research protocols for Ipamorelin typically use doses in the range of 100–300 mcg per injection, given one to three times daily, to align with the body's natural GH pulses. Compare that to MK-677's single daily oral dose — a very different rhythm.

Quick Comparison

  • Route: MK-677 = oral pill | Ipamorelin = subcutaneous injection
  • Common research dose: MK-677 = 25 mg/day | Ipamorelin = 100–300 mcg per injection
  • Duration of action: MK-677 = ~24 hours | Ipamorelin = short pulse (2–3 hours)
  • Selectivity: MK-677 may raise appetite and cause water retention | Ipamorelin is considered more selective with fewer off-target effects in early research
  • Human trial data: MK-677 has more published human trials | Ipamorelin human data is more limited
  • Reported safety signals: MK-677 has documented liver enzyme cases[2] | Ipamorelin long-term human safety data is sparse[4]

How to Choose What to Read About

The right compound to research depends on what question you're asking. Interested in oral convenience and longer GH elevation? MK-677's human trial record gives you more published data to dig into. Interested in pulse-based GH mimicry with high selectivity? Ipamorelin's peptide mechanism is where the emerging literature is headed.

In both cases, dosing details matter enormously. Small differences in dose, timing, and cycle length can change what the research shows. Use our calculator to cross-reference published research doses before interpreting any data.

Check the dedicated pages — MK-677 and Ipamorelin — for full dosing charts sourced directly from published studies. Remember: this is research education, not medical advice. Talk to a qualified clinician before making any health decisions.

Sources

  1. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. — The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534.
  2. Hepatotoxicity induced by MK-677. — BMJ case reports, 2025. PMID 40675653.
  3. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026. PMID 41490200.
  4. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine, 2026. PMID 41476424.
  5. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. — Yonsei medical journal, 2018. PMID 30450851.
  6. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. — Experimental physiology, 2022. PMID 36303408.
See the dosage chart — MK-677
An orally active ghrelin-mimetic GH secretagogue.
MK-677

FAQ

Is MK-677 a peptide like Ipamorelin?
No. MK-677 is a non-peptide small molecule that mimics peptide signals. Ipamorelin is an actual peptide — a short chain of amino acids. This is why MK-677 survives stomach acid and can be taken orally, while Ipamorelin must be injected to avoid being digested before it reaches the bloodstream.
What dose of MK-677 was used in human research?
The most cited early human trial used 25 mg taken orally once daily for seven days in healthy volunteers under caloric restriction. That study was randomized and placebo-controlled, making it one of the stronger early data points. However, dose-response data across longer durations in humans remains limited, and safety signals like liver enzyme changes have since been reported in case studies.
Why is Ipamorelin often combined with CJC-1295 in research?
Ipamorelin triggers a short GH pulse lasting roughly two to three hours. CJC-1295 is a GHRH analog that extends and amplifies that pulse. Researchers combine them to produce a stronger, more sustained GH release. A 2026 sports medicine review noted improved muscle function in animal models with this combination, though human clinical evidence is still very limited.
Are there known safety risks with MK-677?
Yes, some have been documented. Common reported side effects include increased appetite, water retention, and muscle discomfort. A 2025 case report described liver enzyme elevation (hepatotoxicity) in a man who used MK-677 for two months, which resolved after stopping. A separate case report linked MK-677 use to changes in serum lipids and liver enzymes. These are case reports, not large trials, but they are worth factoring into any research review.
For research and educational use only. Not medical advice.